Prostate cancer classification

US10196697B2 · kind B2 · utility

Assignee

• Almac Diagnostics Limited · GB

Inventors

• Steven J. Walker · Portage, US
• Andrena MCCAVIGAN · Lurgan, GB
• Timothy Davison · Hillsborough, GB
• Richard Kennedy · Ocala, US
• Paul Harkin · Great Neck, US
• Laura A. Hill · Lisburn, GB

Key dates

• Filing date: Dec 12, 2014
• Grant date: Feb 5, 2019
• Expiry date: Dec 12, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method is provided for characterizing and/or prognosing prostate cancer in a subject comprising determining the expression level of at least one of CREM, ERRFI1, SRSF5, PDK4, HJURP, PDRG1, TRPM3, PDE4D, FI2, ADAMTS1, ADAMTS9, B3GNT5, CD38, CEBPD, CENPF, DKK1, EMP1, F3, IL1R1, IL8, JUNB, KLFIO, KLF4, LDLR, LGALS3, LPARI, MALAT1, MTUS1, MYBPC1, NFIL3, NR4A3, OAT, PI15, PTGS2, RHOBTB3, RIN2, RNFT2, SELE, SLC15A2, SOCS2, SOCS3, SSTR1, ST6GAL1, TSC22D1, XBP1 and ZFP36 in a sample from the subject. The method may be used to predict the likelihood of metastasis. Also disclosed are methods for diagnosing and selecting treatment for prostate cancer, together with corresponding methods of treatment. Systems, kits and computer programs for performing the methods are also provided.